Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TECH vs SYRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TECH Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

TECH Overall Winner 6-Pillar Tally: TECH 5 – 0 SYRE (1 Tie) Matrix Metrics: TECH 10 – 0 SYRE

As of Nov 16, 2026, Bio-Techne Corp. (TECH) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TECH carries a Unified Composite Score of 53.1/100 (HOLD) at $72.79 (42.8x Forward P/E, 21.7% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TECH vs SYRE
TECH NASDAQ Head-to-Head Winner
Bio-Techne Corp.
Biological Products, (No Disgnostic Substances)
$72.79
-0.01% 1D
Market Cap $11.4B
TTM Revenue $1.23B
Forward P/E 42.8x
Beta / 30D Vol 0.37β · 1% Vol
Unified Composite Score
53.1 / 100 HOLD
Tech 43.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 58.5 · SMA20: $72.71 · SMA50: $72.54
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.5 · SMA20: $98.78 · SMA50: $91.70

6-Pillar Scorecard Institutional Category Breakdown (TECH 5 – 0 SYRE)

Columns: Metric · TECH · SYRE
1. Valuation Multiples TECH
Forward P/E 42.8x N/M
Trailing P/E 66.8x N/M
PEG Ratio 2.18x N/M
EV / Revenue 9.3x N/M
2. Growth & Scale TECH
Revenue Growth (YoY) +4.6% +0.0%
Earnings Growth (YoY) -25.0% -99.7%
TTM Revenue (USD) $1.23B N/A
Market Cap $11.4B $9.8B
3. Profitability & Quality TECH
Gross Margin 66.2% N/A
Operating Margin 21.7% 0.0%
Net Profit Margin 14.0% 0.0%
Return on Equity (ROE) 8.3% -35.0%
4. Balance Sheet & Cash Flow TECH
Cash Generation (TTM) $325M EBITDA N/A
Cash Flow Margin 26.5% EBITDA Mgn N/A
Net Cash / Leverage $13.79 Book/Sh · 8.3% ROE $10.06 Book/Sh · -35.0% ROE
Dividend Yield 0.33% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 40.9% (6th %ile) 87.9% (10th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat TECH
OpEx & R&D Intensity 44.5% of Rev ($547M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TECH (10) vs SYRE (0)
Institutional Metric TECH SYRE Criterion Row Edge
Market Capitalization
Scale
$11.4B $9.8B Larger Scale TECH
Trailing P/E Ratio
Valuation
66.8x N/M Lower Multiple TECH
Forward P/E Ratio
Valuation
42.8x N/M Lower Multiple TECH
Revenue Growth (YoY)
Growth
+4.6% +0.0% Higher Growth TECH
Operating Margin (TTM)
Profitability
21.7% 0.0% Higher Margin TECH
Net Profit Margin
Profitability
14.0% 0.0% Higher Margin TECH
Return on Equity (ROE)
Capital Efficiency
8.3% -35.0% Higher ROE TECH
52-Week Range Position
Momentum
100% ($43–$73) 88% ($22–$111) Stronger Trend TECH
Beta / 30D Volatility
Risk Regime
0.37β · 1% Vol 1.75β · 59% Vol Lower Realized Risk TECH
Unified Institutional Score
Composite Signal
53.1 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite TECH
Trailing 12M Revenue (USD)
Operating Scale
$1.23B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
66.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.18x PEG · 9.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$325M EBITDA ($13.79 Book/Sh · 8.3% ROE) N/A ($10.06 Book/Sh · -35.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +24.81 pp
TECH: +0.3% · SYRE: +25.11%
3M Horizon TECH +8.08 pp
TECH: +0.79% · SYRE: -7.29%
6M Horizon TECH +21.19 pp
TECH: +63.83% · SYRE: +42.64%
1Y Horizon SYRE +321.92 pp
TECH: +19.82% · SYRE: +341.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TECH vs SYRE. Trailing 12-month operating profitability (TECH 21.7% vs SYRE 0.0%) and valuation multiples (TECH 42.8x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TECH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.23B
Gross Margin66.2%
Op. Margin21.7%
ROE / Fwd P/E8.3% · 42.8x
SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TECH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 40.9%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TECH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TECH Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $11.4B market capitalization and 21.7% operating margin.
OpEx & R&D Reinvestment 44.5% of Rev ($547M)
90D Engineering Disclosures 0 Published
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TECH vs SYRE Key Questions & Quantitative Answers

As of Nov 16, 2026, Bio-Techne Corp. (TECH) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TECH carries a Unified Composite Score of 53.1/100 (HOLD) at $72.79 (42.8x Forward P/E, 21.7% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin). Technically, TECH sits in a Neutral phase (RSI 58.5, UNCLASSIFIED options structure) and SYRE sits in a Neutral phase (RSI 53.5, UNCLASSIFIED options structure).

TECH leads the Growth & Scale pillar: TECH posts +4.6% YoY revenue growth and -25.0% YoY earnings growth on $1.23B TTM revenue (66.2% gross margin, 21.7% operating margin), compared with SYRE at +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TECH generates $1.23B in USD-normalized revenue versus N/A for SYRE. In operating R&D and SG&A reinvestment, TECH deploys 44.5% of Rev ($547M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYRE.

TECH screens cheaper on headline valuation multiples. TECH trades at 42.8x Forward P/E, 66.8x Trailing P/E, 2.18x PEG, and 9.3x EV/Revenue (26.5% EBITDA margin), whereas SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TECH (8.3% ROE) versus SYRE (-35.0% ROE) capital efficiency.

In options market volatility and institutional positioning, TECH carries 40.9% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.37β · 1% Vol realized risk). By comparison, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.